Pharmacodynamic & Safety of Patiromer in Children & Adolescents (2-<18 Yrs) With Chronic Kidney Disease and Hyperkalemia
Public ClinicalTrials.gov record NCT03087058. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Open-Label, Multiple Dose Study to Evaluate the Pharmacodynamic Effects, Safety, and Tolerability of Patiromer for Oral Suspension in Children and Adolescents 2 to < 18 Years of Age With Chronic Kidney Disease and Hyperkalemia
Study identification
- NCT ID
- NCT03087058
- Recruitment status
- Terminated
- Study type
- Interventional
- Phase
- Phase 2
- Lead sponsor
- Vifor Pharma, Inc.
- Industry
- Enrollment
- 23 participants
Conditions and interventions
Conditions
Interventions
- Patiromer Drug
Drug
Eligibility (public fields only)
- Age range
- 2 Years to 17 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 6, 2017
- Primary completion
- Jan 12, 2021
- Completion
- Apr 29, 2021
- Last update posted
- Oct 18, 2022
2017 – 2021
United States locations
- U.S. sites
- 10
- U.S. states
- 8
- U.S. cities
- 10
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigator Site 1107 | Palo Alto | California | 94394 | — |
| Investigator Site 1101 | Kansas City | Kansas | 64108 | — |
| Investigator Site 1103 | Baltimore | Maryland | 21287 | — |
| Investigator Site 1102 | The Bronx | New York | 10467 | — |
| Investigator Site 1105 | Cincinnati | Ohio | 45229 | — |
| Investigator Site 1108 | Pittsburgh | Pennsylvania | 15224 | — |
| Investigator Site 1104 | Amarillo | Texas | 79106 | — |
| Investigator Site 1109 | Dallas | Texas | 75235 | — |
| Investigator Site 1113 | Houston | Texas | 77030 | — |
| Investigator Site 1106 | Madison | Wisconsin | 53792 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 20 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03087058, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 18, 2022 · Synced Jul 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03087058 live on ClinicalTrials.gov.